Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.48 |
| ▸ | EP300 | Q09472 | 9/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15538835 | 0.99 | KDM1A (0.47) | KDM1AEP300CREBBPPTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL387125 | 0.99 | KDM1A (0.47) | KDM1AEP300CREBBPPTGS1PTGS2 | |
| SCHEMBL4050547 | 0.86 | KDM1A (0.49) | KDM1AEP300CREBBPPTGS1PTGS2 | |
| SCHEMBL12659968 | 0.83 | TDP1 (0.58) | KDM1APTGS1PTGS2IKBKBCHUK | |
| SCHEMBL15539741 | 0.82 | KCNH2 (0.43) | PTGS1PTGS2KCNH2 | |
| Hydrochloric Acid SCHEMBL384404 | 0.82 | TDP1 (0.61) | KDM1APTGS1PTGS2IKBKBCHUK | |
| SCHEMBL3986213 | 0.81 | PTGS1 (0.43) | PTGS1PTGS2KCNH2 | |
| SCHEMBL12659969 | 0.81 | IKBKB (0.46) | KDM1AEP300PTGS1PTGS2IKBKB | |
| SCHEMBL5564172 | 0.79 | TDP1 (0.63) | KDM1APTGS1PTGS2IKBKBCHUK | |
| SCHEMBL385101 | 0.79 | GPR183 (0.58) | KDM1AEP300PTGS1PTGS2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | KDM1A 4789/4885EP300 4130/4885CREBBP 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.